# Virtual Screening–Guided Discovery of a Selective TRPV1 Pentapeptide Inhibitor with Topical Anti-Allergic Efficacy

**Authors:** Lulu Liu, Wenqian Hou, Qinyi He, Fuchu Yuan, Changrun Guo, Ruxia Liu, Biao Huang, Atikan Wubulikasimu, Mingqiang Rong

PMC · DOI: 10.3390/cells15010079 · Cells · 2026-01-03

## TL;DR

Researchers discovered a selective TRPV1 pentapeptide inhibitor that effectively reduces allergic skin symptoms like itching and redness when applied topically.

## Contribution

A novel, selective TRPV1 pentapeptide inhibitor with proven topical anti-allergic efficacy was rationally designed and validated.

## Key findings

- P5 (DQKNC) inhibited TRPV1 currents with nanomolar potency and high selectivity.
- Topical P5 reduced capsaicin-induced burning pain, erythema, and pruritus in human skin.
- P5 showed negligible effects on cardiac and neuronal ion channels, indicating safety.

## Abstract

Transient receptor potential vanilloid 1 (TRPV1) channels are critical mediators of cutaneous allergic inflammation, contributing to pruritus, erythema, and hypersensitivity in allergic skin disorders. Despite their therapeutic potential, clinically available TRPV1 inhibitors remain limited, leaving effective treatment options lacking. Here, we focused on a self-constructed virtual pentapeptide library and identified a highly selective TRPV1 inhibitor that demonstrated pronounced anti-allergic effects in human skin assays. Through structure-based virtual screening of approximately 200,000 peptide conformations, five candidate pentapeptides, especially P5 (DQKNC), exhibited the inhibition. Electrophysiological recordings showed that P5 inhibited TRPV1 currents with nanomolar potency, while exhibiting negligible effects on major cardiac and neuronal ion channels, highlighting its favorable selectivity and safety profile. In capsaicin-induced human skin hypersensitivity tests, topical P5 significantly reduced burning pain, erythema, and pruritus, with simultaneous application providing the most robust relief. These findings reveal a short peptide with strong TRPV1 selectivity and demonstrable efficacy in alleviating skin inflammation and allergic responses, supporting the notion that rationally designed pentapeptides may represent promising topical therapeutics for allergic skin disorders.

## Linked entities

- **Genes:** TRPV1 (transient receptor potential cation channel subfamily V member 1) [NCBI Gene 7442]
- **Diseases:** hypersensitivity (MONDO:0000605)
- **Species:** Homo sapiens (taxon 9606)

## Full-text entities

- **Genes:** TRPV1 (transient receptor potential cation channel subfamily V member 1) [NCBI Gene 7442] {aka VR1}
- **Diseases:** pruritus (MESH:D011537), pain (MESH:D010146), Allergic (MESH:D004342), allergic skin disorders (MESH:D012871), erythema (MESH:D004890), allergic inflammation (MESH:D007249)
- **Chemicals:** Pentapeptide (-), P5 (MESH:C016883), capsaicin (MESH:D002211)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12786063/full.md

## Figures

4 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12786063/full.md

## References

42 references — full list in the complete paper: https://tomesphere.com/paper/PMC12786063/full.md

---
Source: https://tomesphere.com/paper/PMC12786063